Department of Chemistry, The University of Chicago, Chicago, Illinois 60637, United States.
Department of Pathology, Stanford University School of Medicine, Stanford, California 94305, United States.
J Am Chem Soc. 2024 Aug 28;146(34):24053-24060. doi: 10.1021/jacs.4c07851. Epub 2024 Aug 13.
Macrocyclic peptides are promising scaffolds for the covalent ligand discovery. However, platforms enabling the direct identification of covalent macrocyclic ligands in a high-throughput manner are limited. In this study, we present an mRNA display platform allowing selection of covalent macrocyclic inhibitors using 1,3-dibromoacetone-vinyl sulfone (DBA-VS). Testcase selections on TEV protease resulted in potent covalent inhibitors with diverse cyclic structures, among which cTEV6-2, a macrocyclic peptide with a unique C-terminal cyclization, emerged as the most potent covalent inhibitor of TEV protease described to-date. This study outlines the workflow for integrating chemical functionalization─installation of a covalent warhead─with mRNA display and showcases its application in targeted covalent ligand discovery.
大环肽是共价配体发现的有前途的支架。然而,能够以高通量方式直接鉴定共价大环配体的平台是有限的。在这项研究中,我们提出了一种 mRNA 展示平台,该平台允许使用 1,3-二溴乙酮-乙烯砜 (DBA-VS) 选择共价大环抑制剂。在 TEV 蛋白酶上进行的测试选择产生了具有多种环状结构的强效共价抑制剂,其中 cTEV6-2 是一种具有独特 C 末端环化的大环肽,是迄今为止描述的 TEV 蛋白酶最有效的共价抑制剂。本研究概述了将化学官能化(安装共价弹头)与 mRNA 展示相结合的工作流程,并展示了其在靶向共价配体发现中的应用。